世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界のB細胞非ホジキンリンパ腫薬市場 2018-2022年

Global B-cell non hodgkin lymphoma drugs market 2018-2022

IRTNTR23643

 

出版社 出版年月電子版価格 ページ数
TechNavio
テクナビオ
2018年8月US$2,500
シングルユーザライセンス
107

サマリー

この調査レポートは世界のB細胞非ホジキンリンパ腫薬市場を分析・予測したTechNavioの市場調査報告書です。

Description

About B-Cell Non-Hodgkin Lymphoma Drugs
B-cell non-Hodgkin lymphoma (NHL) is a type of cancer that forms in B-cells. It may be either indolent (slow-growing) or aggressive (fast-growing). Most B-cell lymphomas are non-Hodgkin lymphomas. There are various types of B-cell NHL including Burkitt lymphoma, chronic lymphocytic leukemia (CLL), follicular lymphoma, and mantle cell lymphoma.
Technavio’s analysts forecast the Global B-Cell Non-Hodgkin Lymphoma Drugs Market to grow at a CAGR of 7.52% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the B-cell non-Hodgkin lymphoma drugs market. To calculate the market size, the report considers the revenue generated from the retail sales of B-cell non-Hodgkin lymphoma drugs across the globe.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Technavio's report, B-cell non-Hodgkin lymphoma drugs market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Biogen
- F. Hoffmann-La Roche
- Merck
- Novartis
- Spectrum Pharmaceuticals
Market driver
- Growing government initiatives
- For a full, detailed list, view our report

Market challenge
- High cost of treatment
- For a full, detailed list, view our report

Market trend
- Strong pipeline
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2022 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.



目次

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 05: MARKET SIZING
- Market definition
- Market sizing 2017
- Market size and forecast
PART 06: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 07: PIPELINE LANDSCAPE
PART 08: MARKET SEGMENTATION BY CATEGORY
- Segmentation by category
- Comparison by category
- Small molecules - Market size and forecast 2017-2022
- Biologicals - Market size and forecast 2017-2022
- Market opportunity by category
PART 09: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- B-cell NHL drugs market in Americas
- B-cell NHL drugs market in EMEA
- B-cell NHL drugs market in APAC
- Market opportunity
PART 10: CUSTOMER LANDSCAPE
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 13: MARKET TRENDS
- Strong pipeline
- Strategic alliances
- Advanced technologies
PART 14: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 15: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Biogen
- F. Hoffmann-La Roche
- Merck
- Novartis
- Spectrum Pharmaceutical
PART 16: APPENDIX
- List of abbreviations


Exhibit 01: Parent market
Exhibit 02: Global NHL therapeutics market segmentation
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition: Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global B-cell NHL drugs market 2017-2022 ($ mn)
Exhibit 09: Global B-Cell NHL drugs market: Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition: Five forces 2017
Exhibit 18: Pipeline landscape by development phase
Exhibit 19: Late stage pipeline molecules of B-cell NHL
Exhibit 20: Global B-cell NHL drugs market - Market share by category 2017-2022 (%)
Exhibit 21: Comparison by category
Exhibit 22: Global B-cell NHL drugs market by small molecules 2017-2022 ($ mn)
Exhibit 23: Global B-cell NHL drugs market by small molecules: Year-over-year growth 2018-2022 (%)
Exhibit 24: Global B-cell NHL drugs market by biologicals 2017-2022 ($ mn)
Exhibit 25: Global B-cell NHL drugs market by biologicals: Year-over-year growth 2018-2022 (%)
Exhibit 26: Market opportunity by category
Exhibit 27: Global B-cell NHL drugs market by geography 2017-2022 (%)
Exhibit 28: Regional comparison
Exhibit 29: B-cell NHL drugs market in Americas 2017-2022 ($ mn)
Exhibit 30: B-cell NHL drugs market in Americas: Year-over-year growth 2018-2022 (%)
Exhibit 31: Top 3 countries in Americas
Exhibit 32: B-cell NHL drugs market in EMEA 2017-2022 ($ mn)
Exhibit 33: B-cell NHL drugs market in EMEA: Year-over-year growth 2018-2022 (%)
Exhibit 34: Top 3 countries in EMEA
Exhibit 35: B-cell NHL drugs market in APAC 2017-2022 ($ mn)
Exhibit 36: B-cell NHL drugs market in APAC: Year-over-year growth 2018-2022 (%)
Exhibit 37: Top 3 countries in APAC
Exhibit 38: Market opportunity
Exhibit 39: Customer landscape
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: Biogen - Overview
Exhibit 46: Biogen - Business segments
Exhibit 47: Biogen - Organizational developments
Exhibit 48: Biogen - Geographic focus
Exhibit 49: Biogen - Segment focus
Exhibit 50: Biogen - Key offerings
Exhibit 51: Biogen - Key customers
Exhibit 52: F. Hoffmann-La Roche - Overview
Exhibit 53: F. Hoffmann-La Roche - Business segments
Exhibit 54: F. Hoffmann-La Roche - Organizational developments
Exhibit 55: F. Hoffmann-La Roche - Geographic focus
Exhibit 56: F. Hoffmann-La Roche - Segment focus
Exhibit 57: F. Hoffmann-La Roche - Key offerings
Exhibit 58: F. Hoffmann-La Roche - Key customers
Exhibit 59: Merck - Overview
Exhibit 60: Merck - Business segments
Exhibit 61: Merck - Organizational developments
Exhibit 62: Merck - Geographic focus
Exhibit 63: Merck - Segment focus
Exhibit 64: Merck - Key offerings
Exhibit 65: Merck - Key customers
Exhibit 66: Novartis - Overview
Exhibit 67: Novartis - Business segments
Exhibit 68: Novartis - Organizational developments
Exhibit 69: Novartis - Geographic focus
Exhibit 70: Novartis - Segment focus
Exhibit 71: Novartis - Key offerings
Exhibit 72: Novartis - Key customers
Exhibit 73: Spectrum Pharmaceuticals - Overview
Exhibit 74: Spectrum Pharmaceuticals - Business segments
Exhibit 75: Spectrum Pharmaceuticals - Organizational developments
Exhibit 76: Spectrum Pharmaceuticals - Geographic focus
Exhibit 77: Spectrum Pharmaceuticals - Segment focus
Exhibit 78: Spectrum Pharmaceuticals - Key offerings
Exhibit 79: Spectrum Pharmaceuticals - Key customers

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る